May. 12 at 5:56 AM
$HRTX is a stock I mostly watch on the side ...
This is because I invested heavily in TRVN (Trevena) back in 2021. Some people thought that TRVN could be
$40 to
$60/share, but who really knows. It's ease to use the Total Addressable Market (TAM) and make "conservative" guesses and say even "if we get x% the company make hundreds of millions". Yet, in Trevena case nearly all of the Rx's that went out ended up being returned to the company despite 40+ hospitals saying that they would use there drug ... but, when this "better than morphine" drug actually came to market they didn't.
Part of the problem was that Trevena's Olinyk was far too expensive. About 10x morphine. Braddog's post mentions "Friction". That's a real thing.
https://stocktwits.com/Braddog/message/653033008
IMO, Heron is trying. I'm not going to guess what the s/p is going to be in the future. It certainly isn't going to be TRVN which is now trading at 1¢ and has a total Market Cap of
$9,588!
The other company in this same space I followed was AcelRx Pharmaceuticals which rebranded to Talphera, Inc. (Nasdaq: TLPH) effective January 10, 2024, to reflect a new focus on developing products for medically supervised settings. The name change follows a strategic shift away from acute pain and toward new pipeline candidates, such as the anticoagulant Niyad™
It seems that pain mgt. is a fairly difficult space to invest in.
Pain management is widely considered a challenging investment space, characterized by high regulatory scrutiny, complex clinical trials, and reimbursement difficulties.
While there is massive demand for innovation—nearly 25% of U.S. adults report chronic pain—investment has historically not matched this need, with only a small fraction of venture capital going to pain-focused companies compared to areas like oncology.
Images are notes for my own reference. Thank for the thoughtful posts everyone. Good luck.
